Gilead Sciences (GILD) EBT (2009 - 2026)

Gilead Sciences (GILD) has reported EBT for 18 consecutive years, with -$10.3 billion the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, EBT fell 522.15% year-over-year to -$10.3 billion; the trailing twelve-month figure through Jun 2026 stood at -$2.0 billion (down 127.15% YoY), and the FY2025 full-year result was $9.8 billion, up 1319.71% from the prior year.
• EBT fell to -$10.3 billion in Q2 2026 per GILD's latest filing, from $2.6 billion in the prior quarter.
• Across five years, EBT topped out at $3.6 billion in Q3 2025 and bottomed at -$10.3 billion in Q2 2026.
• Historically, EBT has averaged $860.3 million across 5 years, with a median of $1.8 billion in 2022.
• The sharpest annual moves came in 2023 and 2026: EBT soared 955.26% in 2023, then sank 522.15% in 2026.
• Over 5 years, EBT stood at $2.0 billion in 2022, then dropped by 18.61% to $1.7 billion in 2023, then surged by 31.09% to $2.2 billion in 2024, then slipped by 4.11% to $2.1 billion in 2025, then tumbled by 593.46% to -$10.3 billion in 2026.
• According to Business Quant data, EBT over the past three periods registered -$10.3 billion, $2.6 billion, and $2.1 billion for Q2 2026, Q1 2026, and Q4 2025 respectively.